Component
A-485 p300/CBP catalytic inhibitor
A-485 p300/CBP catalytic inhibitor
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
p300/CBP inhibition blocked the ALCAR-associated proliferation rescue in lipid-depleted ACLY/ACSS2-null HCC cells.
Experimental context and source evidence
- evidence_access
- Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
- experimental_condition
- ALCAR-treated double-knockout cells without A-485 deleted · Mouse ATP-citrate lyase / Acly Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_condition
- ALCAR-treated double-knockout cells without A-485 present · Acetyl-L-carnitine Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_condition
- ALCAR-treated double-knockout cells without A-485 present · A-485 p300/CBP catalytic inhibitor Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_condition
- ALCAR-treated double-knockout cells without A-485 deleted · Mouse acyl-CoA synthetase short-chain family member 2 / Acss2 Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_contrast
- {"intervention": "A-485 plus ALCAR in lipid-depleted double-knockout cells", "comparator": "ALCAR-treated double-knockout cells without A-485", "endpoint": "p300/CBP inhibition blocked the ALCAR-associated proliferation rescue in lipid-depleted ACLY/ACSS2-null HCC cells.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "a-485", "state": "present"}, {"entity_slug": "acetylcarnitine", "state": "present"}, {"entity_slug": "mouse-acly", "state": "deleted"}, {"entity_slug": "mouse-acss2", "state": "deleted"}]} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Mouse HCC cells; A-485; Fig. 6G–H.
- interpretation_status
- Source-derived curation with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
- plain_language
- p300/CBP inhibition blocked the ALCAR-associated proliferation rescue in lipid-depleted ACLY/ACSS2-null HCC cells.
- primary_references
- Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. | https://pubmed.ncbi.nlm.nih.gov/37134161/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10156126/ | https://doi.org/10.1126/sciadv.adf0115
- source_locator
- Reviewed reference hcc-p300-block; A-485 suppressed H3K27 acetylation but not H3K23 acetylation in this comparison. ACC inhibition did not block the growth rescue, separating acetylation from obligatory de novo lipogenesis.
Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 268–274
AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Mouse HCC cells; A-485; Fig. 6G–H. · Recorded from source · Recorded from source
### hcc-p300-block p300/CBP inhibition blocked the ALCAR-associated proliferation rescue in lipid-depleted ACLY/ACSS2-null HCC cells. A-485 suppressed H3K27 acetylation but not H3K23 acetylation in this comparison. ACC inhibition did not block the growth rescue, separating acetylation from obligatory de novo lipogenesis. Model and exposure: Mouse HCC cells; A-485; Fig. 6G–H. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. | 2023 | https://pubmed.ncbi.nlm.nih.gov/37134161/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10156126/ | https://doi.org/10.1126/sciadv.adf0115 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.